Information Provided By: 
Fly News Breaks for June 24, 2016
DHR, FTV
Jun 24, 2016 | 08:36 EDT
Bernstein analyst Steven Winoker initiated Fortive Corp. (FTV) with an Outperform rating and $57 target, noting that Fortive spins off to Danaher (DHR) shareholders in regular way trading on July 5. In conjunction, Winoker increased his Danaher price target to $120 from $112, based on his updated Fortive view and sum-of-the-parts valuation for Danaher, and upgraded Danaher to Outperform from Market Perform.
News For FTV;DHR From the Last 2 Days
FTV
Apr 25, 2024 | 09:48 EDT
FTV
Apr 25, 2024 | 09:46 EDT
FTV
Apr 25, 2024 | 07:20 EDT
FTV
Apr 25, 2024 | 07:15 EDT
FTV
Apr 24, 2024 | 16:14 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
FTV
Apr 24, 2024 | 13:04 EDT
DHR
Apr 24, 2024 | 09:23 EDT
FTV
Apr 24, 2024 | 07:35 EDT
FTV
Apr 24, 2024 | 07:34 EDT
Sees Q2 revenue $1.6B, consensus $1.62B. The company said, "For the second quarter of 2024, Fortive anticipates revenue of approximately $1.6 billion, diluted net earnings per share of $0.57 to $0.60 and adjusted diluted net earnings per share of $0.90 to $0.93."
FTV
Apr 24, 2024 | 07:33 EDT
DHR
Apr 24, 2024 | 07:22 EDT
DHR
Apr 24, 2024 | 06:40 EDT
Baird raised the firm's price target on Danaher to $271 from $259 and keeps an Outperform rating on the shares. The firm said they reported 1Q results above expectations, helped by respiratory testing and bioprocessing upside. The company saw encouraging bioprocessing trends, with orders growing mid-single-digits, and noted normalization of large customer ordering patterns, with management expecting destocking to be largely complete by 2Q24-end.
DHR
Apr 24, 2024 | 06:32 EDT
DHR
Apr 24, 2024 | 05:28 EDT
Barclays raised the firm's price target on Danaher to $270 from $260 and keeps an Equal Weight rating on the shares post the Q1 report. The company's orders came in above expectations, the analyst tells investors in a research note. The firm says bioprocessing names continue to be favored by investors and that it does not see this changing in the near term.
